Research Journal of Pharmacy and Technology

A study was conducted on a novel dipeptidyl peptidase-4 inhibitor, Teneligliptin when given as an add on therapy with oral anti diabetic agents in patients with type 2 diabetes mellitus. Previously diagnosed subjects with type 2 diabetes (T2DM) were assigned 20 mg/day teneligliptin along with other anti-diabetic drugs. At 3 months, levels of glycemic parameters like HbA1C, fasting blood glucose levels, Post Prandial levels as well as non-glycemic parameters like lipid profile (Total cholesterol, LDL, HDL, Triglycerides), hsCRP level, serum creatinine, Blood urea, BMI were compared with those at baseline. Teneligliptin as an add on therapy led to significant reduction in glycemic parameters like HbA1c (1.6±0.97mg/dl), fasting blood glucose (45.86±62.85), and post prandial levels (72.73±47.97) from the baseline values (p <0.000). Significant co relation was observed between change in HbA1c level and baseline HbA1C levels. Significant reduction in the total cholesterol levels were observed (p < 0.000) but other lipid profile parameters like HDL, LDL, and triglycerides were not shown to be statistically significant after treatment. No change in hsCRP level and BMI was observed. Addition of teneligliptin to oral anti diabetic agents led to a significant improvement in glycemic control in subjects with type 2 diabetes mellitus without causing any weight change.